Bot Detector
Download FREE Sample Issue or Article
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

New Perspectives on Vancomycin Use in Home Care, Part 1

Author(s):  Kastango Eric S, Hadaway Lynn

Issue:  Nov/Dec 2001 - High-Tech Compounding
View All Articles in Issue

Page(s):  465-469

New Perspectives on Vancomycin Use in Home Care, Part 1 Page 1
New Perspectives on Vancomycin Use in Home Care, Part 1 Page 2
New Perspectives on Vancomycin Use in Home Care, Part 1 Page 3
New Perspectives on Vancomycin Use in Home Care, Part 1 Page 4
New Perspectives on Vancomycin Use in Home Care, Part 1 Page 5

Download in electronic PDF format for $75

Abstract:  With the advent of new venous access devices (VADs) and medication delivery technology, pharmacists must reconsider the historical literature and administration guidelines that pertain to vancomycin. Current literature1-3 supports the conclusion that there is no direct correlation between vancomycin concentration or rate of administration and side effects (particularly red man syndrome). Venous access devices such as midclavicular catheters, midlines, and peripheral inserted central catheters (PICCs) enable more concentrated solutions of vancomycin to be infused safely without an increased incidence of adverse events. Advances in medication delivery technology ensure the consistency of therapy protocols (including catheter flushing and administration rate) that reduce the potential for adverse events and medication errors, particularly in the unmonitored home setting.

The American Society of Health-System Pharmacists4 states that by fulfilling their responsibilities in pharmaceutical care, pharmacists have a role in meeting the primary care needs of patients. Pharmaceutical care is the direct, responsible provision of medicationrelated care to achieve an outcome that improves a patient’s quality of life. Pharmacists establish relationships with patients to ensure the appropriateness of medication therapy, to verify patients’ understanding of that therapy, and to monitor the effects of treatment. In collaborative drug therapy management, physicians and other prescribers authorize pharmacists to select appropriate medication therapies and regimens and adjust them on the basis of patients’ responses to treatment.

The delivery of pharmaceutical care requires specialized knowledge about pharmacology, vascular access devices and their placement, compounding factors (eg, osmolarity, pH, stability, particulate matter), delivery systems, and patient management. In this article, those factors will be addressed with respect to optimizing the medication delivery of and patient response to vancomycin therapy.

Related Keywords: Catheters, peripheral, characteristics of, Vancomycin, in home care, Vancomycin, infusions, rate of administration, Vancomycin, solutions, osmolarity of, Vancomycin, solutions, pH of, Vancomycin, solutions, stability of


Printer-Friendly Version

Related Articles from IJPC
(Click for Abstract / Details / Purchase)
New Perspectives on Vancomycin Use in Home Care, Part 1
Kastango Eric S
, Hadaway Lynn
Nov/Dec 2001
Pg. 465-469

New Perspectives on Vancomycin Use in Home Care, Part 2: Delivery Systems
Kastango Eric S
, Hadaway Lynn
Jan/Feb 2002
Pg. 55-57

Stability of Vancomycin HCl in MEDICATION CASSETTE Reservoirs
Allen Loyd V Jr
, Stiles M Lou
Mar/Apr 1997
Pg. 123-124

Three Fortified Ophthalmic Solutions: Amikacin 5% Ophthalmic Solution; Ceftazidime 5% Ophthalmic Solution; Vancomycin 5% Ophthalmic Solution
Allen Loyd V Jr
Sep/Oct 2010
Pg. 421

Vancomycin 31-mg/mL Ophthalmic Solution
Allen Loyd V Jr
Nov/Dec 2011
Pg. 508

Use of 8.4% Sodium Bicarbonate in Buffering Commonly Administered Vancomycin Hydrochloride Solutions for Use with Midline or Peripheral Line Catheters
Puertos Enrique
, Spencer Melissa
Jul/Aug 2015
Pg. 334-336

Compatibility and Stability of Cefotaxine, Vancomycin, and Ciprofloxacin in Antibiotic Lock Solutions Containing Heparin
Baker Daniel S
, Waldrop Bruce, Arnold John
Jul/Aug 2010
Pg. 346-349

Vancomycin 5% and Amikacin 2% Ophthalmic Solution
Allen Loyd V Jr
Jan/Feb 2016
Pg. 56

Long-term Stability of Vancomycin Hydrochloride in Oral Solution: The Brand Name Versus a Generic Product
Huvelle Sophie
, Godet Marie, Hecq Jean-Daniel, Gillet Patricia, Jamart Jacques, Galanti Laurence M
Jul/Aug 2016
Pg. 347-350

Vancomycin HCl 50-mg/mL Oral Solution
Allen Loyd V Jr
Jan/Feb 2003
Pg. 64

Vancomycin Gel (Vancomycin Paste, Vanc Paste)
Allen Loyd V Jr
Nov/Dec 1997
Pg. 418

Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration
Kupiec Thomas C
, Ben Michel, Trusley Craig, Trissel Lawrence A
Mar/Apr 2008
Pg. 170-173

Testing the Long-Term Stability of Vancomycin Ophthalmic Solution
McLellan Christine
, Ngo Van, Pasedis Sophia, Dohlman Claes H
Sep/Oct 2008
Pg. 456-459

Vancomycin Hydrochloride 25-mg/mL Solution
Allen Loyd V Jr
Jan/Feb 2011
Pg. 73

Physicochemical and Microbiological Stability of Vancomycin 10-mg/mL Intravitreal Syringes
Bartoll Aaron Puplà
, Bellés Medall Maria Dolores, Peñarrocha Josep Edo, Escrig Laura Solaz, Clemente Ruben Eguren, Azuara Julia Bodega, Piqueres Raul Ferrando
Jul/Aug 2022
Pg. 330-335

Stability of Commercially Available Grape and Compounded Cherry Oral Vancomycin Preparations Stored in Syringes and Cups
Kirk Loren
, Lewis Paul, Luu Yao, Brown Stacy
Mar/Apr 2016
Pg. 159-163

Vancomycin 50 mg/mL in Oral Syrup Suspension
Allen Loyd V Jr
Sep/Oct 2017
Pg. 417

Vancomycin 5-mg/mL Injection
Allen Loyd V Jr
Nov/Dec 2017
Pg. 499

Vancomycin 2% in Silver Sulfadiazine Cream
Allen Loyd V Jr
Nov/Dec 2011
Pg. 509

Stability of Vancomycin in SyrSpend SF
Whaley Paul A
, Voudrie Mark A II
Mar/Apr 2012
Pg. 167-169

Return to Top